Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Therapeutic Advances in Urology
|
December 9, 2024
Plain Language Summary of Publication: Does crushing vibegron 75 mg tablet affect its safety or the amount of vibegron in the body over time in healthy adults?
Jennifer King, Nancy Tuders, Susann Varano, et al.
Journal of Comparative Effectiveness Research
|
August 16, 2023
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
David Staskin, Jeffrey Frankel, Steven G Gregg, et al.
Urogynecology (Philadelphia, Pa.)
|
November 17, 2022
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial
Diane K Newman, Elizabeth Thomas, Heather Greene, et al.
The Journal of Urology
|
February 19, 2020
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
David Staskin, Jeffrey Frankel, Susann Varano, et al.
The Journal of Urology
|
March 9, 2021
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
International Journal of Clinical Practice
|
December 17, 2020
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study
Jeffrey Frankel, Susann Varano, David Staskin, et al.
The Journal of Urology
|
December 28, 2020
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Drugs & Aging
|
January 20, 2021
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
Susann Varano, David Staskin, Jeffrey Frankel, et al.
The Journal of Urology
|
May 22, 2020
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Therapeutics and Clinical Risk Management
|
March 10, 2022
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
Jeffrey Frankel, David Staskin, Susann Varano, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Therapeutic Advances in Urology
|
December 9, 2024
Plain Language Summary of Publication: Does crushing vibegron 75 mg tablet affect its safety or the amount of vibegron in the body over time in healthy adults?
Jennifer King, Nancy Tuders, Susann Varano, et al.
Journal of Comparative Effectiveness Research
|
August 16, 2023
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
David Staskin, Jeffrey Frankel, Steven G Gregg, et al.
Urogynecology (Philadelphia, Pa.)
|
November 17, 2022
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial
Diane K Newman, Elizabeth Thomas, Heather Greene, et al.
The Journal of Urology
|
February 19, 2020
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
David Staskin, Jeffrey Frankel, Susann Varano, et al.
The Journal of Urology
|
March 9, 2021
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
International Journal of Clinical Practice
|
December 17, 2020
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study
Jeffrey Frankel, Susann Varano, David Staskin, et al.
The Journal of Urology
|
December 28, 2020
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Drugs & Aging
|
January 20, 2021
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
Susann Varano, David Staskin, Jeffrey Frankel, et al.
The Journal of Urology
|
May 22, 2020
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Therapeutics and Clinical Risk Management
|
March 10, 2022
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
Jeffrey Frankel, David Staskin, Susann Varano, et al.
Page
of 2